Tranexamic Acid in Pediatric Cardiac Surgery

• Status: Completed
• Trial end date: 2008-04-01
• Target enrollment: 0
• Participant gender: All

Summary

Tranexamic acid(TXA) is an antifibrinolytic agent to reduce blood loss in cardiac surgery. Previous seven RCTs comparing effects of TXA in pediatric cardiac surgery showed conflict results. The reason why they showed mixed results would be the imbalance of patients population with regard to presence of cyanosis. TXA would reduce blood loss in pediatric cardiac surgery with well balanced patients population.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Okayama University
• Treatments: Antifibrinolytic Agents; Tranexamic Acid; Tranylcypromine

Criteria

Inclusion Criteria:

• children undergoing elective cardiac surgery with cardiopulmonary bypass

Exclusion Criteria:

• neonate born within 1 month

• preoperative inotropes

• preoperative mechanical ventilation

• preexisting coagulation disorder

• reoperation within 48 hours

• significant liver or kidney disease

• known allergy to TXA